AI-extracted claim
“Novartis spent 44 percent more on lobbying last quarter than in 2023, surging into the top 10 health lobbying spenders for the first time in years.”
Analyzed on 2026-08-22T05:05:08+00:00 · Last updated 2026-08-22
Plain language: Insufficient evidence was found to render a verdict.
Credibility score
out of 100
Based on 1 source
Low confidence
Original context
Show passage from source article
Novartis spent 44 percent more on lobbying last quarter than in 2023, surging into the top 10 health lobbying spenders for the first time in years.
Extracted from: Pharma lobbying up in 2024 , Politico
Evidence
This analysis is based on a single source. Confidence is low.
Bias distribution of supporting sources
Mean bias -0.10
Community Takes
No Takes have been written on this claim yet. Sign in to write a Take.